FDA’s Risk Disclosure Challenges Highlighted At Contraceptive Advisory Cmte.
Executive Summary
Uncertainty remained the dominant opinion about the risk for blood clots with the four Bayer contraceptives at the conclusion of a Dec. 8 joint meeting of the Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committees. One thing panelists were sure of was that they didn’t want a summary conclusion about the risks in labeling. But they didn’t want a lengthy discussion of data, either.
You may also be interested in...
Contraceptive Compliance Studies May Be Key To Assessing Risk Of Ortho Evra Patch
Some patients in an FDA-funded study had less risk for blood clots than others and finding the reason is a subject for future studies, several members of an advisory panel told FDA Dec. 9. The Reproductive Health Drugs and Drug Safety and Risk Management Committees concluded in a 19-5 vote that the drug’s benefits outweigh its risks.
Non-Contraceptive Use Could Confound Safety Evaluation Of Drospirenone-Containing Products
FDA will seek advisory committee input Dec. 8 on whether and how to adjust labeling and to conduct further studies for contraceptives containing progestin drospirenone because of the drugs’ potential risk for venus thrombotic and thromboembolic events. The agency has a specific study design in mind that it wants sponsors to conduct.
“Drug Facts” Box Not Ready For Prime Time, FDA Advisory Cmte. Says
FDA's Risk Communication Advisory Committee likes the concept of a standardized format in drug promotional labeling and print advertising, but remains concerned that different risk levels for different populations could negate its utility.